Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Form 8 (OPD) (IP Group PLC)

7 Jun 2017 11:48

RNS Number : 4244H
Touchstone Innovations PLC
07 June 2017
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

TOUCHSTONE INNOVATIONS PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

IP GROUP PLC

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

5 June 2017

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES - TOUCHSTONE INNOVATIONS PLC

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

2p Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

-

-

-

-

(2) Cash-settled derivatives:

 

-

-

-

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

-

-

-

-

 

TOTAL:

-

-

-

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

Nil

Details, including nature of the rights concerned and relevant percentages:

Nil

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

3(a) Beneficial and non-beneficial holdings of persons acting in concert with Touchstone Innovations plc in the ordinary shares of IP Group plc:

 

Relevant Person

Number of IP Group plc Ordinary Shares

% of IP Group plc Issued Ordinary Share Capital

RBC Trust Company (International) Limited*

700,000

0.12%

 

* RBC Trust Company (International) Limited is an affiliate of Royal Bank of Canada. RBC Europe Limited (an affiliate of Royal Bank of Canada) is acting as connected adviser to Touchstone Innovations plc.

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

7 June 2017

Contact name:

William Rayner

Telephone number:

+44 20 3053 8859

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEELLFSIRDIDIID
Date   Source Headline
5th Sep 20162:40 pmRNSHolding(s) in Company
24th Aug 20167:01 amRNSCell Medica and UCL collaboration
12th Jul 20167:02 amRNSCell Medica acquires Delenex Therapeutics
6th Jul 20167:00 amRNSEconic raises £5m to develop novel catalyst tech
30th Jun 201612:11 pmRNSPsiOxus and Bristol-Myers Squibb collaboration
28th Jun 20167:00 amRNSStorm Therapeutics raises £12m
21st Jun 20164:35 pmRNSPrice Monitoring Extension
21st Jun 20167:00 amRNSDirector's share purchase
20th Jun 20167:03 amRNSCircassia cat allergy Phase III study
17th Jun 20167:00 amRNSCell Medica and Baylor College of Medicine partner
16th Jun 201610:44 amRNSReplacement Holding(s) in Company
14th Jun 20163:20 pmRNSEdison issues outlook on Imperial Innovations)
14th Jun 20169:00 amRNSHolding(s) in Company
13th Jun 20167:00 amRNSAllotment of Deferred Placing Shares
31st May 20167:00 amRNSFeaturespace closes £6.2 million funding round
26th May 20167:00 amRNS£3 million funding round for Inflowmatix
11th May 201612:32 pmRNSDavid Newlands appointed Chairman
4th May 20164:35 pmRNSPrice Monitoring Extension
4th May 201611:08 amRNSNexeon raises £30m, plans development lab in Asia
4th May 20167:00 amRNSAnalyst and Investor day
29th Apr 20164:35 pmRNSPrice Monitoring Extension
29th Apr 201612:42 pmRNSSale of Innovations portfolio Stanmore Implants
7th Apr 20167:00 amRNSHalf Yearly Report
21st Mar 20167:00 amRNSDr Martin Knight to step down from the board
18th Mar 201612:40 pmRNSNotice of Results
17th Mar 20167:00 amRNSTopiVert reports successful Phase I clinical study
26th Feb 20168:39 amRNSHolding(s) in Company
25th Feb 20163:59 pmRNSHolding(s) in Company
25th Feb 20163:50 pmRNSHolding(s) in Company
25th Feb 20168:53 amRNSHolding(s) in Company
22nd Feb 20165:01 pmRNSAdmission of shares to trading on AIM
22nd Feb 201612:29 pmRNSResult of General Meeting
22nd Feb 20167:00 amRNS£13.5m funding round in Precision Ocular
11th Feb 20162:51 pmRNSHolding(s) in Company
8th Feb 20167:00 amRNSInnovations leads £5m Series A round in Aqdot
4th Feb 20166:08 pmRNSResult of Placing
4th Feb 20167:00 amRNSPlacing to raise £100 million
2nd Feb 20167:00 amRNSMISSION Therapeutics raises £60 million
26th Jan 20167:00 amRNSInivata completes £31.5m Series A funding round
25th Jan 20167:00 amRNSInnovations joins Apollo consortium
18th Jan 20167:00 amRNSInnovations invests £25m in new £50m UCL Tech Fund
2nd Dec 20157:00 amRNSKesios Therapeutics raises £19 million
19th Nov 20151:51 pmRNSResult of AGM
4th Nov 20151:40 pmRNSGrant of share options
28th Oct 20157:00 amRNSPosting of Annual Report and Notice of AGM
22nd Oct 20157:00 amRNSLeads £1.5m seed funding into AI pioneer, Telectic
14th Oct 20157:00 amRNSFinal Results
22nd Sep 20154:10 pmRNSNotice of Results
12th Aug 20157:00 amRNSIssue of Equity
4th Aug 20157:01 amRNS£2.5m funding round in Oxford Biotrans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.